Product Description
Taisho R&D is developing ts-142, an Oral DORA Antagonist for insomnia
Mechanisms of Action: DORA Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Taisho
Company Location:
Company Founding Year: 1912
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Insomnia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05461352 |
TS142-302 | P3 |
Completed |
Insomnia |
2024-03-07 |
3% |
2025-03-01 |
Primary Endpoints|Treatments |
jRCT2071230009 |
jRCT2071230009 | P1 |
Recruiting |
Insomnia |
2023-09-30 |
|||
jRCT2031220463 |
jRCT2031220463 | P1 |
Recruiting |
Insomnia |
1970-01-01 |
|||
jRCT2031220208 |
jRCT2031220208 | P3 |
Active, not recruiting |
Insomnia |
2024-05-15 |
|||
jRCT2031220209 |
jRCT2031220209 | P3 |
Recruiting |
Insomnia |
2024-01-15 |
Recent News Events
Date |
Type |
Title |
|---|
